warfarin and Cerebral-Arterial-Diseases

The WASID trial showed no advantage of warfarin over aspirin for preventing the primary endpoint of ischemic stroke, brain hemorrhage, or vascular death. In analyses of selected subgroups, there was no definite benefit from warfarin. Warfarin reduced the risk of the primary endpoint among patients with basilar artery stenosis, but there was no reduction in stroke in the basilar artery territory or benefit for vertebral artery stenosis or posterior circulation disease in general.

Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cerebral Arterial Diseases; Constriction, Pathologic; Female; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; United States; Warfarin

Topics: Autopsy; Cerebral Angiography; Cerebral Arterial Diseases; Cerebral Arteries; Female; Humans; Middle Aged; Pons; Rupture, Spontaneous; Subarachnoid Hemorrhage; Warfarin